Nanosonics Limited (NNCSF) Research

Nanosonics Limited, in conjunction with its subsidiaries, functions as an infection prevention enterprise, serving both Australian and international markets. The company's core activities involve the production and supply of the trophon ultrasound probe disinfector, alongside its complementary consumables and accessories. Furthermore, Nanosonics is committed to the research, development, and market introduction of innovative infection control and decontamination products and related technologies. Its product portfolio features the trophon2, a sophisticated device for high-level disinfection of ultrasound probes; trophon EPR, a specialized low-temperature, high-level disinfection solution specifically for intra-cavity ultrasound transducers; and Nanosonics AuditPro, a comprehensive system for managing compliance with infection control workflows. Established in 2000, Nanosonics Limited maintains its corporate headquarters in Macquarie Park, Australia.

Market snapshot

Symbol
NNCSF
Price
$2.36
Day change
0.00%
Market cap
$989.4M
P/E ratio
48.91x
52-week range
2.01-3.0575
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Next earnings
in 2 months

Peer companies

  • Arjo AB (publ) (ARRJF)
  • Hogy Medical Co.,Ltd. (HGYMF)
  • LifeTech Scientific Corporation (LFTSF)
  • Panamera Holdings Corporation (PHCI)
  • Safilo Group S.p.A. (SAFLF)
  • Safilo Group S.p.A. (SAFLY)
  • SMS Co., Ltd. (SMSZF)
  • Tobii Dynavox AB (publ) (TDVXF)

Open Nanosonics Limited (NNCSF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.